← Leaderboards
Susan L Greenspan
Beth Israel Deaconess Medical Center
$27,746,173
Attributed
$28,072,562
Total exposure
35
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,447,325 · 36
By mechanism
R01$16,342,079 · 6
P30$15,531,212 · 6
T32$2,479,625 · 1
M01$2,054,000 · 21
K24$1,601,534 · 1
K07$438,875 · 1
Top collaborators
- Christine E Kistler1 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Kenneth Jay Mukamal$8,885,225
- Alice A. Arnold$975,709
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchOsteoporosisBone DensityHuman SubjectTrainingCommunitiesResearch PersonnelFemaleResourcesPostmenopauseFundingProgramsLong-Term CareHuman Therapy EvaluationAgingElderlyNeglectUnited States National Institutes Of HealthUniversitiesMonitorSafetyMultidisciplinaryCohortPharmaceutical Preparations
Grant awards (161)
Preserving Geriatric Muscle with an Osteoporosis Medication$652,778
R01 · FY2025 · AG · contact PI
Preserving Geriatric Muscle with an Osteoporosis Medication$664,631
R01 · FY2024 · AG · contact PI
Innovative Approach to Geriatric Osteoporosis$537,263
R01 · FY2024 · AG · contact PI
Leadership & Administrative Core (LAC)$398,503
P30 · FY2024 · AG · contact PI
Preserving Geriatric Muscle with an Osteoporosis Medication$681,384
R01 · FY2023 · AG · contact PI
Innovative Approach to Geriatric Osteoporosis$551,841
R01 · FY2023 · AG · contact PI
Leadership & Administrative Core (LAC)$129,358
P30 · FY2023 · AG · contact PI
Pittsburgh Older Americans Independence Center$1,272,919
P30 · FY2022 · AG · contact PI
Innovative Approach to Geriatric Osteoporosis$560,723
R01 · FY2022 · AG · contact PI
Pitt Integrated Clinical and Geroscience Research Training Program$365,797
T32 · FY2022 · AG · contact PI
Leadership & Administrative Core (LAC)$132,102
P30 · FY2022 · AG · contact PI
Pittsburgh Older Americans Independence Center$1,354,754
P30 · FY2021 · AG · contact PI
Innovative Approach to Geriatric Osteoporosis$570,836
R01 · FY2021 · AG · contact PI
Pitt Integrated Clinical and Geroscience Research Training Program$350,296
T32 · FY2021 · AG · contact PI
Leadership & Administrative Core (LAC)$140,114
P30 · FY2021 · AG · contact PI
Pittsburgh Older Americans Independence Center$1,246,326
P30 · FY2020 · AG · contact PI
Sustaining Skeletal Health in Frail Elderly$920,744
R01 · FY2020 · AG · contact PI
Innovative Approach to Geriatric Osteoporosis$587,200
R01 · FY2020 · AG · contact PI
Leadership & Administrative Core (LAC)$128,900
P30 · FY2020 · AG · contact PI
Pitt Integrated Clinical and Geroscience Research Training Program$109,638
T32 · FY2020 · AG · contact PI
Long-Term Care Research Network$87,775
K07 · FY2020 · AG · contact PI
Pittsburgh Older Americans Independence Center$930,406
P30 · FY2019 · AG · contact PI
Sustaining Skeletal Health in Frail Elderly$725,631
R01 · FY2019 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders-Phase 2$576,995
R01 · FY2019 · AG · contact PI
Pitt Integrated Clinical and Geroscience Research Training Program$303,177
T32 · FY2019 · AG · contact PI
Sustaining Skeletal Health in Frail Elderly - S1 Competing Revision$209,455
R01 · FY2019 · AG · contact PI
Research Career Development Component (RCDC) (KL2)$187,909
P30 · FY2019 · AG · contact PI
Leadership Administrative Core$131,977
P30 · FY2019 · AG · contact PI
Long-Term Care Research Network$87,775
K07 · FY2019 · AG · contact PI
Pittsburgh Older Americans Independence Center$930,406
P30 · FY2018 · AG · contact PI
Sustaining Skeletal Health in Frail Elderly$739,648
R01 · FY2018 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders-Phase 2$590,408
R01 · FY2018 · AG · contact PI
Research Career Development Component (RCDC) (KL2)$186,476
P30 · FY2018 · AG · contact PI
Sustaining Skeletal Health in Frail Elderly$155,600
R01 · FY2018 · AG · contact PI
Leadership Administrative Core$130,971
P30 · FY2018 · AG · contact PI
Long-Term Care Research Network$87,775
K07 · FY2018 · AG · contact PI
Pitt Clinical Research Training Program in Geriatrics and Gerontology$1
T32 · FY2018 · AG · contact PI
Pittsburgh Older Americans Independence Center$930,406
P30 · FY2017 · AG · contact PI
Sustaining Skeletal Health in Frail Elderly$751,310
R01 · FY2017 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders-Phase 2$605,359
R01 · FY2017 · AG · contact PI
Research Career Development Component (RCDC) (KL2)$183,336
P30 · FY2017 · AG · contact PI
Pittsburgh Older Americans Independence Center$144,566
P30 · FY2017 · AG · contact PI
Leadership Administrative Core$128,767
P30 · FY2017 · AG · contact PI
Long-Term Care Research Network$87,775
K07 · FY2017 · AG · contact PI
Pitt Clinical Research Training Program in Geriatrics and Gerontology$2,149
T32 · FY2017 · AG · contact PI
Pittsburgh Older Americans Independence Center$930,406
P30 · FY2016 · AG · contact PI
Sustaining Skeletal Health in Frail Elderly$757,184
R01 · FY2016 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders-Phase 2$613,971
R01 · FY2016 · AG · contact PI
Pitt Clinical Research Training Program in Geriatrics and Gerontology$456,551
T32 · FY2016 · AG · contact PI
Research Career Development Component (RCDC) (KL2)$181,797
P30 · FY2016 · AG · contact PI
Leadership Administrative Core$127,686
P30 · FY2016 · AG · contact PI
Long-Term Care Research Network$87,775
K07 · FY2016 · AG · contact PI
Pittsburgh Older Americans Independence Center$930,406
P30 · FY2015 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders-Phase 2$625,437
R01 · FY2015 · AG · contact PI
Pitt Clinical Research Training Program in Geriatrics and Gerontology$446,865
T32 · FY2015 · AG · contact PI
Research Career Development Component (RCDC) (KL2)$187,436
P30 · FY2015 · AG · contact PI
Leadership Administrative Core$131,644
P30 · FY2015 · AG · contact PI
Pittsburgh Older Americans Independence Center$852,084
P30 · FY2014 · AG · contact PI
Pitt Clinical Research Training Program in Geriatrics and Gerontology$445,151
T32 · FY2014 · AG · contact PI
Pittsburgh Older Americans Independence Center$852,084
P30 · FY2013 · AG · contact PI
Research Career Development Core$257,057
P30 · FY2013 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders$91,483
R01 · FY2013 · AG · contact PI
Research Career Development Core$271,679
P30 · FY2012 · AG · contact PI
Osteoporosis in Older Men and Women$179,857
K24 · FY2012 · DK · contact PI
Maintenance of Skeletal Integrity in Frail Elders$479,971
R01 · FY2011 · AG · contact PI
Research Career Development Core$272,804
P30 · FY2011 · AG · contact PI
Osteoporosis in Older Men and Women$179,857
K24 · FY2011 · DK · contact PI
Maintenance of Skeletal Integrity in Frail Elders$510,243
R01 · FY2010 · AG · contact PI
Research Career Development Core$276,727
P30 · FY2010 · AG · contact PI
Osteoporosis in Older Men and Women$179,857
K24 · FY2010 · DK · contact PI
Maintenance of Skeletal Integrity in Frail Elders$734,507
R01 · FY2009 · AG · contact PI
Research Career Development Core$288,219
P30 · FY2009 · AG · contact PI
Osteoporosis in Older Men and Women$179,857
K24 · FY2009 · DK · contact PI
Maintenance of Skeletal Integrity in Frail Elders$98,998
R01 · FY2009 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders$556,836
R01 · FY2008 · AG · contact PI
RESEARCH AND DEVELOPMENT CORE$267,900
P30 · FY2008 · AG · contact PI
Osteoporosis in Older Men and Women$179,335
K24 · FY2008 · DK · contact PI
Maintenance of Skeletal Integrity in Frail Elders$150,999
R01 · FY2008 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders$16,748
R01 · FY2008 · AG · contact PI
Maintenance of Skeletal Integrity in Frail Elders$521,427
R01 · FY2007 · AG · contact PI
RESEARCH AND DEVELOPMENT CORE$270,359
P30 · FY2007 · AG · contact PI
Osteoporosis in Older Men and Women$147,365
K24 · FY2007 · DK · contact PI
RESEARCH AND DEVELOPMENT CORE$250,718
P30 · FY2006 · AG · contact PI
Osteoporosis in Older Men and Women$143,859
K24 · FY2006 · DK · contact PI
Prevention of Osteoporosis in Men with Prostate Cancer$269,156
R01 · FY2005 · DK
RESEARCH AND DEVELOPMENT CORE$248,234
P30 · FY2005 · AG
Osteoporosis in Older Men and Women$140,455
K24 · FY2005 · DK
ONCE WKLY BISPHOSPHONATE PREVENTING OSTEOPOROSIS IN HYPOGONDAL MEN$92,935
M01 · FY2005 · RR
PREVENTION OSTEOPOROSIS PREMENOPAUSAL/POSTMENOPAUSAL WOMEN W/BREAST CANCER$64,622
M01 · FY2005 · RR
BONE LOSS IN MEN W/PROSTATE CANCER TREATED W/ANDROGEN DEPRIVATION THERAPY$26,648
M01 · FY2005 · RR
F/U PTH ALENDRONATE COMBO TRMNT OSTEOPOROSIS PATH II$19,319
M01 · FY2005 · RR
Prevention of Osteoporosis in Men with Prostate Cancer$269,383
R01 · FY2004 · DK
RESEARCH AND DEVELOPMENT CORE$245,776
P30 · FY2004 · AG
Osteoporosis in Older Men and Women$137,150
K24 · FY2004 · DK
Bone Loss in Men with Prostate Cancer$115,742
M01 · FY2004 · RR
Bisphosphonate Prevention of Osteoporosis in Men$114,724
M01 · FY2004 · RR
Prevention Osteoporosis in Premenopause/Postmenopause$46,551
M01 · FY2004 · RR
PTH and Alendronate in the Treatment of Osteoporosis$16,535
M01 · FY2004 · RR
Bariatric Surgery Effect on Bone Mass/ Bone Metabolism$3,816
M01 · FY2004 · RR
Lasofoxifene for Women at Risk for Osteoporosis$1,780
M01 · FY2004 · RR
Prevention of Osteoporosis in Men with Prostate Cancer$270,290
R01 · FY2003 · DK
Osteoporosis in Older Men and Women$133,942
K24 · FY2003 · DK
Prevention of Osteoporosis in Men with Prostate Cancer$293,640
R01 · FY2002 · DK
BISPHOSPHONATE-HORMONAL THERAPY FOR OSTEOPOROSIS$0
M01 · FY2002 · RR
EFFICACY OF QUS 2 ULTRASONOMETER FOR DIAGNOSIS OF OSTEOPOROSIS$0
M01 · FY2002 · RR
REFERENCE RANGE FOR THE QUS 2 ULTRASONOMETER FOR EVALUATION OF OSTEOPOROSIS$0
M01 · FY2002 · RR
PRECISION ASSESSMENT OF QUS 2 ULTRASONOMETER$0
M01 · FY2002 · RR
CALCANEAL BONE ASSESSMENT TECHNOLOGIES TO DUAL X RAY ABSORPTIOMETRY$0
M01 · FY2002 · RR
PHASE III CYCLIC TILUDRONATE--POSTMENOPAUSAL OSTEOPOROSI$0
M01 · FY2002 · RR
ALENDRONATE ONCE WEEKLY FOR OSTEOPOROSIS PREVENTION$0
M01 · FY2002 · RR
ALENDRONATE ONCE &TWICE WEEKLY FOR OSTEOPOROSIS TREATMENT$0
M01 · FY2002 · RR
SCREENING HIGH RISK POPULATION FOR CLINICALLY SIGNIFICANT GAUCHER DIS$0
M01 · FY2002 · RR
RALOXIFENE HYDROCHLORIDE, PLACEBO AND PREMARIN IN PREVENTION OF OSTEOPOROSIS$0
M01 · FY2002 · RR
ALENDRONATE ONCE &TWICE WEEKLY FOR OSTEOPOROSIS TREATMENT$0
M01 · FY2001 · RR
EFFICACY OF QUS 2 ULTRASONOMETER FOR DIAGNOSIS OF OSTEOPOROSIS$0
M01 · FY2001 · RR
REFERENCE RANGE FOR THE QUS 2 ULTRASONOMETER FOR EVALUATION OF OSTEOPOROSIS$0
M01 · FY2001 · RR
PRECISION ASSESSMENT OF QUS 2 ULTRASONOMETER$0
M01 · FY2001 · RR
CALCANEAL BONE ASSESSMENT TECHNOLOGIES TO DUAL X RAY ABSORPTIOMETRY$0
M01 · FY2001 · RR
PHASE III CYCLIC TILUDRONATE--POSTMENOPAUSAL OSTEOPOROSI$0
M01 · FY2001 · RR
ALENDRONATE ONCE WEEKLY FOR OSTEOPOROSIS PREVENTION$0
M01 · FY2001 · RR
SCREENING HIGH RISK POPULATION FOR CLINICALLY SIGNIFICANT GAUCHER DIS$0
M01 · FY2001 · RR
BISPHOSPHONATE-HORMONAL THERAPY FOR OSTEOPOROSIS$0
M01 · FY2001 · RR
RALOXIFENE HYDROCHLORIDE, PLACEBO AND PREMARIN IN PREVENTION OF OSTEOPOROSIS$0
M01 · FY2001 · RR
BONE LOSS PREVENTION AFTER ACUTE HIP FRACTURE IN THE ELDERLY$193,916
M01 · FY2000 · RR
BONE LOSS PREVENTION AFTER ACUTE HIP FRACTURE IN THE ELDERLY$193,916
M01 · FY2000 · RR
ALENDRONATE ON BONE DENSITY MAINTENANCE IN FEMALE NURSING HOME PATIENTS$193,916
M01 · FY2000 · RR
ALENDRONATE ON BONE DENSITY MAINTENANCE IN FEMALE NURSING HOME PATIENTS$193,916
M01 · FY2000 · RR
EFFECT OF ALENDRONATE, ESTROGEN AND COMBINATION THERAPY FOR OSTEOPOROSIS$193,916
M01 · FY2000 · RR
EFFICACY OF MK-0677 AND ALENDRONATE ON BONE TURNOVER AND DENSITY$193,916
M01 · FY2000 · RR
EFFECT OF ALENDRONATE, ESTROGEN AND COMBINATION THERAPY FOR OSTEOPOROSIS$193,916
M01 · FY2000 · RR
EFFICACY OF MK-0677 AND ALENDRONATE ON BONE TURNOVER AND DENSITY$193,916
M01 · FY2000 · RR
PRECISION ASSESSMENT OF QUS 2 ULTRASONOMETER$0
M01 · FY2000 · RR
PRECISION ASSESSMENT OF QUS 2 ULTRASONOMETER$0
M01 · FY2000 · RR
CALCANEAL BONE ASSESSMENT TECHNOLOGIES TO DUAL X RAY ABSORPTIOMETRY$0
M01 · FY2000 · RR
CALCANEAL BONE ASSESSMENT TECHNOLOGIES TO DUAL X RAY ABSORPTIOMETRY$0
M01 · FY2000 · RR
CALCANEAL BONE ASSESSMENT TECHNOLOGIES TO DUAL X RAY ABSORPTIOMETRY$0
M01 · FY2000 · RR
PHASE III CYCLIC TILUDRONATE--POSTMENOPAUSAL OSTEOPOROSI$0
M01 · FY2000 · RR
PHASE III CYCLIC TILUDRONATE--POSTMENOPAUSAL OSTEOPOROSI$0
M01 · FY2000 · RR
PHASE III CYCLIC TILUDRONATE--POSTMENOPAUSAL OSTEOPOROSI$0
M01 · FY2000 · RR
ALENDRONATE ONCE WEEKLY FOR OSTEOPOROSIS PREVENTION$0
M01 · FY2000 · RR
ALENDRONATE ONCE WEEKLY FOR OSTEOPOROSIS PREVENTION$0
M01 · FY2000 · RR
ALENDRONATE ONCE WEEKLY FOR OSTEOPOROSIS PREVENTION$0
M01 · FY2000 · RR
ALENDRONATE ONCE &TWICE WEEKLY FOR OSTEOPOROSIS TREATMENT$0
M01 · FY2000 · RR
ALENDRONATE ONCE &TWICE WEEKLY FOR OSTEOPOROSIS TREATMENT$0
M01 · FY2000 · RR
ALENDRONATE ONCE &TWICE WEEKLY FOR OSTEOPOROSIS TREATMENT$0
M01 · FY2000 · RR
SCREENING HIGH RISK POPULATION FOR CLINICALLY SIGNIFICANT GAUCHER DIS$0
M01 · FY2000 · RR
SCREENING HIGH RISK POPULATION FOR CLINICALLY SIGNIFICANT GAUCHER DIS$0
M01 · FY2000 · RR
SCREENING HIGH RISK POPULATION FOR CLINICALLY SIGNIFICANT GAUCHER DIS$0
M01 · FY2000 · RR
BISPHOSPHONATE-HORMONAL THERAPY FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
BISPHOSPHONATE-HORMONAL THERAPY FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
BISPHOSPHONATE-HORMONAL THERAPY FOR OSTEOPOROSIS$0
M01 · FY2000 · RR
RALOXIFENE HYDROCHLORIDE, PLACEBO AND PREMARIN IN PREVENTION OF OSTEOPOROSIS$0
M01 · FY2000 · RR
RALOXIFENE HYDROCHLORIDE, PLACEBO AND PREMARIN IN PREVENTION OF OSTEOPOROSIS$0
M01 · FY2000 · RR
RALOXIFENE HYDROCHLORIDE, PLACEBO AND PREMARIN IN PREVENTION OF OSTEOPOROSIS$0
M01 · FY2000 · RR
EFFICACY OF QUS 2 ULTRASONOMETER FOR DIAGNOSIS OF OSTEOPOROSIS$0
M01 · FY2000 · RR
EFFICACY OF QUS 2 ULTRASONOMETER FOR DIAGNOSIS OF OSTEOPOROSIS$0
M01 · FY2000 · RR
EFFICACY OF QUS 2 ULTRASONOMETER FOR DIAGNOSIS OF OSTEOPOROSIS$0
M01 · FY2000 · RR
REFERENCE RANGE FOR THE QUS 2 ULTRASONOMETER FOR EVALUATION OF OSTEOPOROSIS$0
M01 · FY2000 · RR
REFERENCE RANGE FOR THE QUS 2 ULTRASONOMETER FOR EVALUATION OF OSTEOPOROSIS$0
M01 · FY2000 · RR
REFERENCE RANGE FOR THE QUS 2 ULTRASONOMETER FOR EVALUATION OF OSTEOPOROSIS$0
M01 · FY2000 · RR
PRECISION ASSESSMENT OF QUS 2 ULTRASONOMETER$0
M01 · FY2000 · RR